Ariad Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ARIA)

$23.99 0.00 (0.00 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$23.99
Today's RangeN/A
52-Week Range$4.67 - $23.99
VolumeN/A
Average Volume15.70 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Receive ARIA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARIA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ARIA
CUSIP04033A10
Phone+1-617-4940400

Debt

Debt-to-Equity Ratio-11.28%
Current Ratio3.17%
Quick Ratio3.15%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.18)
Net IncomeN/A
Net Margins-60.47%
Return on EquityN/A
Return on Assets-17.16%

Miscellaneous

Employees459
Outstanding Shares194,390,000

Ariad Pharmaceuticals (NASDAQ:ARIA) Frequently Asked Questions

What is Ariad Pharmaceuticals' stock symbol?

Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."

How were Ariad Pharmaceuticals' earnings last quarter?

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) posted its earnings results on Thursday, July, 28th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.70. The pharmaceutical company had revenue of $65.30 million for the quarter, compared to analysts' expectations of $60.64 million. The firm's revenue for the quarter was up 133.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. View Ariad Pharmaceuticals' Earnings History.

Where is Ariad Pharmaceuticals' stock going? Where will Ariad Pharmaceuticals' stock price be in 2017?

5 brokers have issued 1-year price objectives for Ariad Pharmaceuticals' shares. Their predictions range from $16.00 to $24.00. On average, they expect Ariad Pharmaceuticals' stock price to reach $22.00 in the next twelve months. View Analyst Ratings for Ariad Pharmaceuticals.

Who are some of Ariad Pharmaceuticals' key competitors?

How do I buy Ariad Pharmaceuticals stock?

Shares of Ariad Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ariad Pharmaceuticals' stock price today?

One share of Ariad Pharmaceuticals stock can currently be purchased for approximately $23.99.

How can I contact Ariad Pharmaceuticals?

Ariad Pharmaceuticals' mailing address is 125 Binney St, CAMBRIDGE, MA 02142-1123, United States. The pharmaceutical company can be reached via phone at +1-617-4940400.


MarketBeat Community Rating for Ariad Pharmaceuticals (ARIA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  423 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  737
MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ariad Pharmaceuticals (NASDAQ:ARIA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.102.102.102.10
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.54$16.54$16.54$15.39
Price Target Upside: 30.15% downside30.15% downside30.15% downside35.02% downside

Ariad Pharmaceuticals (NASDAQ:ARIA) Consensus Price Target History

Price Target History for Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals (NASDAQ:ARIA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2017SunTrust BanksDowngradeBuy -> Hold$24.00N/AView Rating Details
1/10/2017CowenReiterated RatingBuy$16.00N/AView Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
1/10/2017BarclaysUpgradeUnderweight -> Equal Weight$9.00 -> $24.00N/AView Rating Details
1/10/2017Jefferies GroupDowngradeBuy -> Hold$11.00 -> $24.00N/AView Rating Details
12/10/2016William BlairReiterated RatingOutperform$15.00N/AView Rating Details
12/1/2016JMP SecuritiesReiterated RatingMarket PerformN/AView Rating Details
11/3/2016Deutsche BankInitiated CoverageHold$9.50N/AView Rating Details
10/24/2016J P Morgan Chase & CoDowngradeNeutral -> Underweight$9.97 -> $7.00N/AView Rating Details
6/20/2016Royal Bank of CanadaReiterated RatingHoldN/AView Rating Details
2/22/2016Goldman Sachs GroupLower Price Target$7.00 -> $5.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Ariad Pharmaceuticals (NASDAQ:ARIA) Earnings History and Estimates Chart

Earnings by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals (NASDAQ ARIA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016Q316($0.19)($0.14)$42.93 million$34.30 millionViewListenView Earnings Details
7/28/2016Q216($0.11)$0.59$60.64 million$65.30 millionViewListenView Earnings Details
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details
2/19/2015Q414($0.12)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details
11/5/2014Q314($0.30)($0.27)$16.50 million$14.70 millionViewListenView Earnings Details
8/6/2014Q214($0.27)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details
11/3/2011$0.02$0.10ViewN/AView Earnings Details
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Ariad Pharmaceuticals (NASDAQ:ARIA) Earnings Estimates

2017 EPS Consensus Estimate: ($1.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.21)($0.23)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.22)($0.22)($0.22)
Q4 20172($0.57)($0.21)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ariad Pharmaceuticals (NASDAQ ARIA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 86.97%
Insider Trades by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Trades by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals (NASDAQ ARIA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Daniel M BollagVPSell32,000$23.78$760,960.00View SEC Filing  
10/24/2016Timothy P ClacksonInsiderSell19,638$9.56$187,739.28View SEC Filing  
10/3/2016Daniel M BollagVPSell47,384$13.46$637,788.64View SEC Filing  
9/28/2016Timothy P ClacksonInsiderSell8,750$13.98$122,325.00View SEC Filing  
9/22/2016Timothy P ClacksonInsiderSell20,000$13.43$268,600.00View SEC Filing  
9/15/2016Timothy P ClacksonInsiderSell59,369$11.73$696,398.37View SEC Filing  
8/22/2016Timothy P ClacksonInsiderSell19,436$10.47$203,494.92View SEC Filing  
8/12/2016Timothy P ClacksonInsiderSell25,000$10.50$262,500.00View SEC Filing  
7/22/2016Timothy P ClacksonInsiderSell18,286$8.11$148,299.46View SEC Filing  
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.60View SEC Filing  
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ariad Pharmaceuticals (NASDAQ ARIA) News Headlines

Source:
DateHeadline
Ariad Pharmaceuticals settles investor lawsuit for $3.5 million - ReutersAriad Pharmaceuticals settles investor lawsuit for $3.5 million - Reuters
www.reuters.com - December 1 at 3:24 PM
Ariad Pharmaceuticals settles investor lawsuit for $3.5 millionAriad Pharmaceuticals settles investor lawsuit for $3.5 million
www.reuters.com - December 1 at 8:13 AM
Head to Head Survey: Ariad Pharmaceuticals (ARIA) & Heat Biologics (HTBX)Head to Head Survey: Ariad Pharmaceuticals (ARIA) & Heat Biologics (HTBX)
www.americanbankingnews.com - November 27 at 5:22 PM
Takeda Chief Seeks to Forge Identity Beyond Japan With DealsTakeda Chief Seeks to Forge Identity Beyond Japan With Deals
www.bloomberg.com - November 16 at 9:21 PM
Pulse Biosciences Announces Transition of Board of Directors, Extends Appreciation to Retiring Members and ... - Business Wire (press release)Pulse Biosciences Announces Transition of Board of Directors, Extends Appreciation to Retiring Members and ... - Business Wire (press release)
www.businesswire.com - November 3 at 9:20 AM
Incyte Reports 2017 Third-Quarter Financial Results And Updates On Key Clinical ProgramsIncyte Reports 2017 Third-Quarter Financial Results And Updates On Key Clinical Programs
www.thestreet.com - November 1 at 3:27 AM
Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs - Business Wire (press release)Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs - Business Wire (press release)
www.businesswire.com - October 31 at 5:18 PM
Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical OperationsBlueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations
www.bizjournals.com - October 10 at 5:24 PM
​Shire officially inks sublease for former Ariad site in Cambridge - Boston Business Journal​Shire officially inks sublease for former Ariad site in Cambridge - Boston Business Journal
www.bizjournals.com - October 5 at 6:50 PM
Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal ... - Business Wire (press release)Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal ... - Business Wire (press release)
www.businesswire.com - September 28 at 8:00 AM
Incyte seeking $666.6 million from stock saleIncyte seeking $666.6 million from stock sale
www.bizjournals.com - September 12 at 9:20 PM
Why Acadia Pharma Could be Worth $10 Billion | Investopedia - InvestopediaWhy Acadia Pharma Could be Worth $10 Billion | Investopedia - Investopedia
www.investopedia.com - September 11 at 3:53 PM
Eton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors - PR Newswire (press release)Eton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors - PR Newswire (press release)
www.prnewswire.com - September 9 at 3:50 PM
Eton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors - PR Newswire (press release)Eton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors - PR Newswire (press release)
www.prnewswire.com - September 9 at 3:50 PM
Eton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of DirectorsEton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors
finance.yahoo.com - September 7 at 4:01 PM
Takeda Pharmaceutical Prescribes Stability After Rough StartTakeda Pharmaceutical Prescribes Stability After Rough Start
www.msn.com - September 5 at 10:42 PM
Takeda CEO Prescribes Stability After Rough StartTakeda CEO Prescribes Stability After Rough Start
www.msn.com - September 5 at 5:39 PM
Judge OKs ex-Ariad employees SEC pact after questioning fairnessJudge OKs ex-Ariad employee's SEC pact after questioning fairness
www.reuters.com - August 16 at 9:28 PM
Compugen Welcomes Paul Sekhri as its New Chairman of the Board - PR Newswire (press release)Compugen Welcomes Paul Sekhri as its New Chairman of the Board - PR Newswire (press release)
www.prnewswire.com - August 3 at 2:54 AM
Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical ProgramsIncyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs
www.businesswire.com - August 1 at 4:57 PM
Japanese drugmaker Takeda posts stronger profit as US sales jump - NasdaqJapanese drugmaker Takeda posts stronger profit as US sales jump - Nasdaq
www.nasdaq.com - July 29 at 3:45 PM
UPDATE 1-Japanese drugmaker Takeda posts stronger profit as US sales jump - ReutersUPDATE 1-Japanese drugmaker Takeda posts stronger profit as US sales jump - Reuters
www.reuters.com - July 28 at 5:10 PM
Ex-Ariad employees husband charged in US with insider trading - Business InsiderEx-Ariad employee's husband charged in US with insider trading - Business Insider
www.businessinsider.com - July 22 at 3:56 PM
Ex-Ariad employees husband charged with insider tradingEx-Ariad employee's husband charged with insider trading
www.reuters.com - July 22 at 3:34 AM
Ex-Ariad employees husband charged with insider trading - Reuters - ReutersEx-Ariad employee's husband charged with insider trading - Reuters - Reuters
www.reuters.com - July 21 at 3:30 AM
Ex-Ariad employees husband charged in U.S. with insider trading - ReutersEx-Ariad employee's husband charged in U.S. with insider trading - Reuters
www.reuters.com - July 20 at 5:26 PM
What Sprycel Could Mean for Bristol-Myers SquibbWhat Sprycel Could Mean for Bristol-Myers Squibb
finance.yahoo.com - July 10 at 4:02 PM
Merrimack: A Special Situation With A Compelling Risk/RewardMerrimack: A Special Situation With A Compelling Risk/Reward
seekingalpha.com - July 6 at 5:23 PM
​SEC charges two former Ariad Pharmaceuticals executives with ... - Boston Business Journal​SEC charges two former Ariad Pharmaceuticals executives with ... - Boston Business Journal
www.bizjournals.com - June 29 at 5:06 PM
SEC charges three with insider trading in cancer drug company - MarketWatchSEC charges three with insider trading in cancer drug company - MarketWatch
www.marketwatch.com - June 27 at 3:45 PM
Mersana Therapeutics Kicks Off A Major IPO WeekMersana Therapeutics Kicks Off A Major IPO Week
seekingalpha.com - June 26 at 9:14 PM
Bellevue Group AG Buys Align Technology Inc, Anthem Inc, Walgreens Boots Alliance Inc, Sells ...Bellevue Group AG Buys Align Technology Inc, Anthem Inc, Walgreens Boots Alliance Inc, Sells ...
www.nasdaq.com - May 12 at 4:10 PM
Alnylam Pharma (ALNY) Names Manmeet S. Soni as CFO - StreetInsider.comAlnylam Pharma (ALNY) Names Manmeet S. Soni as CFO - StreetInsider.com
www.streetinsider.com - May 9 at 9:09 AM
Takeda Announces Publication of ALUNBRIG™ (brigatinib) Pivotal Phase 2 ALTA Clinical Trial Data in Journal of Clinical OncologyTakeda Announces Publication of ALUNBRIG™ (brigatinib) Pivotal Phase 2 ALTA Clinical Trial Data in Journal of Clinical Oncology
www.businesswire.com - May 8 at 10:49 AM
Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & TakedaMonday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda
www.nasdaq.com - April 30 at 2:27 AM
General American Investors Co Inc Buys Ensco PLC, Johnson Controls International PLC, Liberty ...General American Investors Co Inc Buys Ensco PLC, Johnson Controls International PLC, Liberty ...
www.nasdaq.com - April 29 at 4:14 PM
Evercore Partners (EVR) CEO Ralph Schlosstein on Q1 2017 Results - Earnings Call TranscriptEvercore Partners' (EVR) CEO Ralph Schlosstein on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 3:53 PM
Ariad Pharmaceuticals (ARIA) Flat with Quarterly Loss ProjectedAriad Pharmaceuticals (ARIA) Flat with Quarterly Loss Projected
www.baystreet.ca - April 12 at 11:48 AM
Tocagen IPO Could Garner Significant Investor AttentionTocagen IPO Could Garner Significant Investor Attention
seekingalpha.com - April 11 at 8:05 AM
7-Eleven to Buy Sunoco Shops in Record $3.3 Billion U.S. Bet7-Eleven to Buy Sunoco Shops in Record $3.3 Billion U.S. Bet
www.bloomberg.com - April 7 at 3:38 PM
After Soaring to $150, Can Incyte Stir Up More Upside?After Soaring to $150, Can Incyte Stir Up More Upside?
www.thestreet.com - March 15 at 3:49 PM
Trump???s Immigration Plans an Overhang on Biotech ETFs?Trump???s Immigration Plans an Overhang on Biotech ETFs?
www.nasdaq.com - March 2 at 3:51 PM
BRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals - ReutersBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals - Reuters
www.reuters.com - February 18 at 3:34 PM
BRIEF-Takeda Pharmaceutical completes acquisition of ARIAD PharmaceuticalsBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals
www.reuters.com - February 17 at 6:32 PM
Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol USMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US
www.prnewswire.com - February 16 at 8:41 PM
Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol USMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US
www.prnewswire.com - February 16 at 8:41 PM
Takeda Announces Completion of Acquisition of ARIAD Pharmaceuticals (ARIA)Takeda Announces Completion of Acquisition of ARIAD Pharmaceuticals (ARIA)
www.streetinsider.com - February 16 at 8:41 PM
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition oARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
biz.yahoo.com - February 16 at 8:41 PM
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition oARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
biz.yahoo.com - February 16 at 8:41 PM
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition oARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
biz.yahoo.com - February 16 at 8:41 PM

SEC Filings

Ariad Pharmaceuticals (NASDAQ:ARIA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ariad Pharmaceuticals (NASDAQ:ARIA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ariad Pharmaceuticals (NASDAQ ARIA) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.